Thomas Miller/Linkedin
Jun 16, 2025, 09:14
Thomas Miller: Unlocking Smarter BCL-2 Inhibitor Therapies After EHA2025
Thomas Miller, Principal Investigator at Institut Paoli-Calmettes, shared a post on LinkedIn:
“Unlocking Smarter BCL-2 Inhibitor Therapies After EHA2025
Excellent final day at EHA2025. Institut Paoli-Calmettes was particularly engaged by the dedicated session on BCL-2 inhibitor therapies, highlighted by Sylvain Garciaz’s insightful presentation on inherent and acquired resistance mechanisms.
This critical discussion sparks a vital question: How can we develop smarter strategies to utilize BCL-2 inhibitors, circumvent multi-drug resistance, and unlock new combination opportunities, especially for the elderly patient population?
At Institut Paoli-Calmettes, we are committed to exploring these avenues, pushing the boundaries of research to enhance treatment efficacy and improve patient outcomes.
Let’s continue this crucial conversation and collaborate on innovative solutions!”
More posts featuring EHA2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 5, 2025, 10:29
Sep 5, 2025, 08:57
Sep 5, 2025, 08:57